Login Register
icon_bulk_orderBulk order Acrobiosystems for English
0
There is no goods in the shopping cart !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > FKBP12

FKBP12

Brief Information

Name:FK506-binding protein 1A
Target Synonym:Peptidyl-Prolyl Cis-Trans Isomerase FKBP1A,FK506-Binding Protein, T-Cell, 12-KD,FK506-Binding Protein 1A (12kD),Protein Kinase C Inhibitor 2,FK506-Binding Protein 12,FK506 Binding Protein12,FK506-Binding Protein 1,FKBP12-Exip3,Calstabin 1,PPIASE,PKC12,PKCI2,Tacrolimus Binding Protein 1A,FKBP12C,FK506 Binding Protein 1A, 12kDa,12 KDa FK506-Binding Protein,Immunophilin FKBP12,12 KDa FKBP,Rotamase,FKBP Prolyl Isomerase 1A,FKBP1,FKBP12,FKBP-12,PPIase FKBP1A,FK506-binding protein 1A,Calstabin-1,FKBP-
Number of Launched Drugs:1
Number of Drugs in Clinical Trials:1
Lastest Research Phase:Approved

Product ListCompare or Buy

By Product Status:
By Product Category:
By Species:
By Tag:
By Conjugate:
Cat. No. Species Product Description Structure Purity Feature
FKA-H5122 Human Human FKBP12 / FKBP1A Protein, His Tag
FKA-H5122-structure
FKA-H5122-sds

Synonym Name

FKBP1A,FKBP1,Calstabin-1,FKBP12,Rotamase,PKC12,PPIASE

Background

Peptidyl-prolyl cis-trans isomerase FKBP1A, a member of the FKBP-type PPIase family and FKBP1 subfamily, is also known as FK506-binding protein 1A, immunophilin FKBP12 and 12 kDa FK506-binding protein, which contains one PPIase FKBP-type domain. FKBP1A is a cis-trans prolyl isomerase that binds the immunosuppressants FK506 (tacrolimus) and rapamycin (sirolimus).FKBP1A interacts with several intracellular signal transduction proteins including type I TGF-beta receptor. FKBP1A can also interact with multiple intracellular calcium release channels including the tetrameric skeletal muscle ryanodine receptor. Furthermore, FKBP1A can recruite SMAD7 to ACVR1B which prevents the association of SMAD2 and SMAD3 with the activin receptor complex, thereby blocking the activin signal.

Clinical and Translational Updates

Public Drug Information

Name Research Code Research Phase Company First Brand Name First Approved Country First Indication First Approved Company First Approved Date Indications Clinical Trials
Tacrolimus Hydrate FK-506MR; FK-506E; FK-506; MR-4; RTU-007; LCP-Tacro; FR-900506; L-679934 Approved Astellas Pharma Inc Protopy, Graceptor (as hydrate), Protopic, Prograf (as hydrate), Hecoria (as hydrate), Hexal, Envarsus XR, Talymus, 普乐可复, Advagraf, Envarsus, Modigraf, Astagraf XL, TacroBell United States Rejection of lung transplantation Astellas Pharma Inc 1993-01-01 Infertility, Female; Nephrosis, Lipoid; Lymphedema; Conjunctivitis; Psoriasis; Amputation, Traumatic; Conjunctivitis, Allergic; Surgical Wound Infection; Asthma; Pigmentation Disorders; Colitis, Ulcerative; Rejection in heart transplantation; Nephrotic Syndrome; Brain Death; Wounds and Injuries; Renal Insufficiency, Chronic; Keratoconjunctivitis; Coronary Restenosis; Dermatitis, Atopic; Vitiligo; Peripheral Nerve Injuries; Encephalitis; Crohn Disease; Edema; Kidney Failure, Chronic; Dermatomyositis; Myasthenia Gravis; Liver Failure; Reperfusion Injury; Medication Adherence; Polymyositis; Breast Cancer Lymphedema; Genital Diseases, Male; Bone marrow transplant rejection; Glomerulonephritis, IGA; Rejection of liver transplantation; Keratoplasty rejection; Rejection of renal transplantation; Rejection of lung transplantation; Cystitis; Primary Graft Dysfunction; Renal Insufficiency; Lupus Erythematosus, Cutaneous; Kidney Diseases; Arthritis, Rheumatoid; Graft vs Host Disease; Rejection of organ transplantation; Details

Clinical Drug Information

Name Research Code Research Phase Company Indications Clinical Trials
Rimiducid AP-1903 Phase 2 Clinical Ariad Pharmaceuticals Inc Carcinoma, Acinar Cell; Prostatic Neoplasms, Castration-Resistant; Multiple Myeloma; Uveal melanoma; Blastic Plasmacytoid Dendritic Cell Neoplasm; Carcinoma, Adenoid Cystic; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Anemia, Aplastic; Prostatic Neoplasms; Osteopetrosis; Metabolic Diseases; Breast Neoplasms; Colorectal Neoplasms; Immune System Diseases; Carcinoma, Mucoepidermoid; Leukemia, Myeloid, Acute; Lymphoma; Lymphoma, Non-Hodgkin; Carcinoma, Pancreatic Ductal; Lymphohistiocytosis, Hemophagocytic; Urogenital Neoplasms; Leukemia, Biphenotypic, Acute; Anemia, Sickle Cell; Congenital Bone Marrow Failure Syndromes; Prostatic Diseases; Carcinoma, Non-Small-Cell Lung; Squamous Cell Carcinoma of Head and Neck; Lymphoma, B-Cell; Bone Marrow Neoplasms; Hematologic Neoplasms; Leukemia; Primary Immunodeficiency Diseases; Ovarian Neoplasms; Leukemia, Lymphoid; Immunoproliferative Disorders; Lymphatic Diseases; Thalassemia; Stomach Neoplasms; Carcinoma, Renal Cell; Leukemia, Myelogenous, Chronic, BCR-ABL Positiv Details

This web search service is supported by Google Inc.

totop
Call us
Call us
North America: +1 800-810-0816 (Toll Free)
Asia & Pacific: +86 400-682-2521
Fax
Fax
+1 888-377-6111
Address
Address
1 Innovation Way, Newark, DE 19711, USA

Leave a message